MedTrace Logo

Phenotyping and Genotyping of Duffy Antigen

NCT05527119 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2023-11-08

No results posted yet for this study

Summary

Malaria remains the world's leading parasitic endemic. Almost half of the world's population lives in endemic areas. Many at-risk people in African countries remain without access to malaria control. Malaria kills approximately 400,000 people each year, most of whom are children under the age of 5 in Africa. Since 2005, an increasing number of Plasmodium vivax infections have been observed in Duffy-negative populations in South America and Africa, calling into question the essential role of the PvDBP-DARC interaction. The objective of the investigators is therefore to study and understand the invasion pathways used by Plasmodium vivax in Duffy-negative subjects.

Conditions

  • Plasmodium Vivax

Sponsors & Collaborators

  • University Hospital, Strasbourg, France

    lead OTHER

Principal Investigators

  • Didier MENARD, MD, PhD · Service Laboratoire de Parasitologie et Mycologie Médicale-PTM - CHU de Strasbourg - France

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-11
Primary Completion
2023-07-11
Completion
2023-09-11

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05527119 on ClinicalTrials.gov